A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Description

The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.

Conditions

Healthy

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.

Exploratory Study of the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic Arizona, Scottsdale, Arizona, United States, 85259

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.).
  • * Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire.
  • * Only those with an absence of symptoms will eligible to participate.
  • * For healthy volunteers, will include prior surgery altering the esophagus, stomach, and intestine (except appendectomy).
  • * Chronic daily use of medications affecting GI secretion or motor function.
  • * The presence of any GI-motility affecting systemic diseases or untreated psychiatric disease.
  • * Pregnancy.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Mayo Clinic,

John DiBaise, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2024-12